Novel Lung Functional Imaging for Personalized Radiotherapy

Inclusion Criteria

• •Primary lung cancer or metastatic disease to the lungs to be treated with either conventionally-fractionated radiotherapy (CFRT) or hypo-fractionated stereotactic ablative radiotherapy (SABR).
• •Age restriction and/or gender/ethnic restrictions: Patients must be ≥18 years of age. There are no gender or ethnic restrictions.
• •Concurrent chemotherapy is allowed, but not required.
• •Life expectancy with treatment should be ≥6 months in the estimation of the treating physicians.
• •Zubrod performance status ≤2
• •Adequate marrow and hepatic function defined as Hgb ≥8; platelets ≥100k; ANC≥1500; LFTs ≤2x upper limit of normal and creatinine ≤1.3 or creatinine clearance of ≥50
• •Patient must be able to provide study specific informed consent prior to study entry.